Operational impact of COVID-19

Thursday, 26 March 2020 

The impact of COVID-19 on Recipharm’s worldwide operations continues to be monitored daily. We see a negative impact on performance primarily due to staff absence at several locations and we continue to prioritise operations to optimise outputs to support customer and patient needs in the most effective manner. The lock down measures announced in India are impacting our employees commuting to work and has led to a temporary shutdown of operations in Paonta Sahib and Karnal. However, the pharmaceutical industry is clearly prioritized by the Indian government, and we remain in dialogue with local authorities to ensure that employees are able to travel to work unhindered. The manufacturing in Bengaluru remains operational. One of our manufacturing facilities in Portugal has temporarily suspended production as a precautionary measure, but is estimated to resume at the end of March. All of our other factories continue to operate albeit with delays for certain incoming materials and outbound shipments. Due to the dedication and efforts of our staff we still do not see any serious interruptions in our supply chains.

We are putting significant effort and resources to ensure continued supply to our customers and patients by adapting work schedules, shifts patterns and overtime work whilst putting non-manufacturing activities on hold for the time being. This means that we are operating in a sub-optimal manner. Other precautionary measures include a cessation of employee travel, supporting home working and enhancing health and safety procedures in the manufacturing facilities and laboratories. 

Recipharm continues to follow all governmental recommendations whilst at the same time working to mitigate any disruptions. Our highest priority is to ensure that we uphold our responsibilities to employees, customers, patients and partners. This means striving to deliver the highest quality of service whilst also focusing on the safety and well-being of our workforce and extended community.

Contact information

Erik Haeffler, Vice President Manufacturing Services & Head of Sustainability, erik.haeffler@recipharm.com, + 46 8 602 52 85